A new approach to treatment-resistant cancer
Cancer can return because some cancer cells survive treatment. The tumour microenvironment - the conditions within and around a tumour - can protect these resistant cells and allow them to drive regrowth.
OncoTherics is developing drugs that use this protective environment to activate treatment. These unidirectional hypoxia-activated prodrugs (uHAPs) are designed to penetrate tumours and activate irreversibly inside cancer cells with very low oxygen levels. The active drug is then retained within those cells.
Our aim is to complement established therapies by addressing the resistant cancer cells that conventional treatment can leave behind.
Opportunity
OncoTherics is advancing two complementary cancer therapeutics:
- AQ4N – our lead clinical programme in newly diagnosed glioblastoma, supported by demonstrated activation in human tumours and Phase I clinical experience.
- OCT1002 – a separately patented, second-generation asset in advanced preclinical development.
Building on development in the UK and Poland, we are seeking investment to renew AQ4N clinical supply, advance regulatory and early clinical work in the USA, and complete comparative studies to support OCT1002’s progression towards clinical trials.
OncoTherics has been funded to date by its Founders, Private Investors and regional grant funding in Poland. OncoTherics was a beneficiary of the regional operational program of the Małopolskie Voivodeship for the years 2014-2020. This grant funding supported the development of OCT1002.
wartość projektu: 19 357 662,37 PLN
wkład funduszy Europejskich: 11 718 069,36 PLN
